Evidence map›Paper›PMID 41286393›Full record

ReviewFamilial cancer2025

The clinical spectrum of paediatric NF2- related schwannomatosis.

Dorothy Halliday, Lucy Hanington

Abstract readReview
PubMed Publisher
In one paragraph

Review in Familial cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Dorothy HallidayDepartment of Clinical Genetics, Oxford University Hospitals NHS Foundation Trust, Oxford, UK. Dorothy.Halliday@ouh.nhs.uk.ORCID 0000-0002-1098-8599
Lucy HaningtonDepartment of Clinical Genetics, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The clinical spectrum of paediatric NF2-SWN is broad and differs from that seen in the cohort of patients presenting over age 30, where symptoms typically relate to enlarging schwannoma, meningioma or ependymoma. Paediatric cases tend to have a multisystemic presentation with a high tumour burden and significant physical and psychological morbidity. Visual impairment as well as dermatological and non-tumour neurological features are common. Genetic testing characteristically identifies a germline pathogenic variant (often truncating) in the NF2 gene. This review explores the spectrum of clinical disease that arises in NF2-SWN when presenting in childhood.

Indexed as

NeurilemmomaNeurofibromatosesNeurofibromatosis 2Neurofibromin 2Skin NeoplasmsChildGerm-Line MutationHumansNeurofibromin 2NF2 protein, humanNF2-related schwannomatosisNF2-SWNPaediatric clinical features

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.